Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Arcus Biosciences Inc (RCUS) COM USD0.0001

Sell:$8.45 Buy:$8.47 Change: $0.03 (0.36%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$8.45
Buy:$8.47
Change: $0.03 (0.36%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$8.45
Buy:$8.47
Change: $0.03 (0.36%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcus Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on the discovery and development of cancer immunotherapy. Its pipeline includes AB928, AB680, AB122, and AB154. AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.It is in the Phase-I clinical trial. AB680 is a potent and selective inhibitor of CD73 and is in the pre-clinical stage of development. AB122 is an anti-PD-1 antibody and is in the Phase-I dose-escalation trial. AB154 is a humanized anti-TIGIT antibody.

Contact details

Address:
3928 Point Eden Way
HAYWARD
94545-3719
United States
Telephone:
+1 (510) 6946200
Website:
https://www.arcusbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RCUS
ISIN:
US03969F1093
Market cap:
$372.30 million
Shares in issue:
45.85 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Terry Rosen
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Juan Jaen
    President, Co-Founder, Director
  • Rekha Hemrajani
    Chief Financial Officer, Chief Operating Officer
  • Jason Barker
    Principal Financial Officer, Principal Accounting Officer
  • William Grossman
    Chief Medical Officer
  • Eric Hoefer
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.